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Introduction: Juvenile idiopathic arthritis (JIA) is one of the most common chronic diseases 
with childhood onset. It comprises different subtypes of which the systemic onset subtype 
is often resistant to treatment. With the advent of biological treatment with tumor necrosis 
factor-α (TNFα)-inhibitors, the clinical outcome of JIA has improved considerably, but only 
for subtypes other than systemic JIA. Substantial evidence shows that the proinflammatory 
cytokine interleukin-6 (IL-6) plays a pivotal role in systemic JIA. The blockage of IL-6 action 
by tocilizumab, a humanized anti-IL-6-receptor monoclonal antibody, could therefore be an 
effective treatment of systemic JIA.
Aims: The purpose of this article was to review the clinical trials of tocilizumab and to discuss 
its place in the treatment of JIA with the focus on the systemic onset of disease.
Evidence review: Two phase II studies and one phase III clinical trial of tocilizumab 
demonstrating the clinical efficacy and safety in systemic onset JIA have been published. Within 
those studies, sustained and high response rates of clinical improvement have been achieved 
with American College of Rheumatology Pediatric criteria (ACRPed) 30, 50, and 70 observed 
in 98%, 94%, and 90% of patients, respectively, after 48 weeks. One study regarding the clinical 
efficacy of tocilizumab for the treatment of oligo- and polyarticular JIA has been presented 
only as a conference abstract.
Place in therapy: The very promising results seen so far in patients with severe systemic 
JIA and acceptable tolerability gives tocilizumab a central role in the future therapy in 
controlling this disease. No other biological therapy has achieved similar high response 
rates when treating with tocilizumab 8 mg/kg every two weeks to patients with systemic 
onset JIA, but direct comparison of the efficacy of different biological agents are not yet 
available.
Keywords: tocilizumab, anti-IL-6-receptor antibody, biologics, systemic, juvenile idiopathic 
arthritis
Core evidence place in therapy summary for tocilizumab in the treatment   
of juvenile idiopathic arthritis
Outcome measure Evidence Implications
Patient-oriented evidence
improvement of symptoms 
 
reduction of fever  
Tolerability  
Long-term safety 
 
Clear  
 
Substantial  
Clear  
Limited  
 
reduction of joint pain and improvement  
of joint motion 
rapid normalization of temperature  
Few infusion reactions  
Upper respiratory tract infections observed 
but long-term observation are not at hand
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Scopes, aims, and objectives
Tocilizumab (Actemra®, Chugai Pharmaceutical Co., Ltd. 
and F Hoffmann-La Roche) is a humanized anti-interleukin-6 
(IL-6)-receptor antibody used in the targeted therapy of 
rheumatoid arthritis (RA) and juvenile idiopathic arthritis 
(JIA). Tocilizumab blocks the activity of the proinflam-
matory cytokine, IL-6, which exerts a central role in both 
diseases. Within recent years, tocilizumab has been used 
for RA patients with treatment-resistant disease. The aim of 
this article was to review the clinical trials of tocilizumab 
for the use in systemic onset JIA and to discuss its role in 
the treatment strategy for this disease.
Methods
A review of the medical literature regarding tocilizumab 
was performed. Articles related to tocilizumab on PubMed 
(http://www.ncbi.nlm.nih.gov) using the search terms 
“tocilizumab” (117), “tocilizumab AND juvenile idiopathic 
arthritis” (26), and “anti-IL-6-receptor blockade AND 
juvenile idiopathic arthritis” (9) were selected for the review. 
The search was updated on February 20, 2009. Articles not 
written in English were excluded. Furthermore, the search 
term “tocilizumab AND rheumatoid arthritis” (79) was used 
to review clinical trials on adult patients with RA. In addition, 
selected abstracts from the Annual Meetings of the American 
College of Rheumatology (ACR) and of the European League 
Against Rheumatism (EULAR) in 2007 and 2008 were used.
Disease overview
Juvenile idiopathic arthritis is a collective term for different 
patterns of arthritis of unknown cause in children.1 All 
of them are defined as chronic arthritis lasting for more 
than six weeks in the absence of any known cause in a 
child aged under 16 years. JIA is classified according to 
the onset of the disease into seven subtypes: systemic, 
persistent oligoarticular, extended oligoarticular, rheumatoid 
factor-positive polyarticular, rheumatoid factor-negative 
polyarticular, psoriatic, and enthesitis-related arthritis 
subtypes. The disease is among the most frequent chronic 
diseases starting in childhood and in population-based 
studies using the International League of Associations for 
Rheumatology (ILAR) criteria, an annual incidence of 
14–15 per 100,000 has been reported.2,3
Systemic onset JIA, representing about 10% of JIA, is a 
subtype quite distinct from the other subtypes characterized 
by a quotidian, spiking fever lasting more than two weeks, 
nonfixed erythematous skin rash, generalized lymphade-
nopathy, hepatosplenomegaly, or serositis.4 Arthralgia 
and myalgia can be prominent during fever attacks. 
The arthritis, which may not be present during the early 
phase of the disease, is often presented as a symmetrical 
polyarticular arthritis. Marked increases in the acute phase 
reactants are observed resulting in at times very high levels 
of C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR). Leukocytosis, predominantly neutrophils, is 
commonly observed, as well as thrombocytosis, which 
may reflect the exacerbations of the disease.
The course of systemic onset JIA can be monocyclic, 
polycyclic, or persisting with destructive arthritis. The 
overall outcome of the disease is poor with a high risk of 
long-term functional impairment.5 A severe, life-threatening 
complication to systemic onset JIA is macrophage 
activation syndrome, a secondary form of hemophagocytic 
lymphohistiocytosis, presented with prolonged fever, 
pancytopenia, elevated liver transaminases, coagulopathy, 
and high levels of triglycideride and ferritin.6 Further-
more, growth failure, osteoporosis, secondary amyloidosis 
are other severe complications of the disease.
(Continued)
Outcome measure Evidence Implications
Disease-oriented evidence
reduction in synovitis 
 
reduction of anemia 
Reduction of inflammatory response 
 
Maintenance of response during 
treatment
 
Clear 
 
Clear  
Substantial  
 
Clear 
 
improvement in number of swollen joints and 
joints with limitation in motion  
rapid increase in hemoglobin  
rapid decrease in CrP, ESr, neutrophils and 
platelet count  
Long-term efficacy only during treatment
Economic evidence 
Cost effectiveness
 
Unclear
 
Long-term pharmacoeconomic studies missing
Abbreviations: CrP, C-reactive protein; ESr, erythrocyte sedimentation rate.Core Evidence 2009:4 183
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The role of IL-6 in the pathogenesis 
of JIA
Interleukin (IL)-6 is a 26 kD glycoprotein consisting of 
184 amino acids which has previously been assigned 
different names such as B-cell differentiation factor (BCDF), 
Interferon-β2, a hybridoma/plastocytoma growth factor. 
Later, these names were replaced by IL-6.7 IL-6 is produced 
by a variety of cells of which several participate during 
inflammation such as T- and B-cells, monocytes, fibroblasts, 
and endothelial cells.
Function of IL-6 is mediated through two membrane 
proteins, the membrane-bound IL-6R, an 80 kD ligand-binding 
receptor, and gp130, a 130 kD signal transducing element. 
In addition there is a soluble form of IL-6R present in serum. 
When binding to IL-6, both soluble and membrane IL-6R 
connects to gp130 on the membrane whereby the intracellular 
signal activating the Jak-STAT pathway is mediated.8,9
During acute inflammation IL-6 stimulates hepatocytes 
to produce acute-phase proteins such as CRP, haptoglobin, 
fibrinogen, α1-antitrypsin, or serum amyloid A. IL-6 
stimulates the production of hepcidin, an iron regulatory 
peptide hormone which reduces iron transport in the 
intestines and inhibits the release of iron from macrophages 
leading to anemia. Differentiation of osteoclasts is stimu-
lated by IL-6 leading to joint destruction and osteoporosis.
Abnormal expression of the proinflammatory cytokines 
IL-1, IL-6, and tumor necrosis factor-α (TNFα) is seen in 
systemic JIA. It has been demonstrated by several studies that 
IL-6 is significantly elevated in the blood and synovial fluid 
of patients with systemic JIA.10–13 The level of IL-6 fluctuates 
with the characteristic spiking fever, which is not the case for 
the increased levels of TNFα. The high levels of IL-6, also 
being responsible for the impaired growth, thrombocytosis 
and chronic anemia, lead to the suggestion that systemic JIA 
is a IL-6-mediated disease.14 IL-6 and IL-1RA, being induced 
by IL-6, correlates with systemic JIA disease activity, which 
is not the case for IL-1 and TNFα.15 IL-6 form complexes 
with its soluble receptor, sIL-6R, which trigger gp130 dimeri-
sation and signaling. Also, elevated concentration of sIL-6R 
has been found during active disease.16
In family studies the -174G allele of IL-6 gene has been 
confirmed as a susceptibility gene for systemic JIA, since it 
correlates with higher levels of IL-6.17,18
Outcome measures
The American College of Rheumatology Pediatric (ACRPed) 
criteria for the definition of improvement of the clinical 
outcome measures for JIA was proposed by Giannini and 
colleagues.19 A patient is considered to have responded to 
therapy (ACRPed30) if there is an improvement in at least 
three out of six variables (active joint count, number of joints 
with limited range of motion, parent/patient global assessment 
on a visual analogue scale, physician global assessment 
on a visual analogue scale, first hour ESR (mm/hour), 
Childhood Health Assessment Questionnaire) by at least 
30% and worsening in not more than one variable by more 
than 30% (Table 1). For the ACRPed50 and ACRPed70, 
an improvement of at least 50% or 70%, respectively, must 
be achieved in three out of six of the above variables with 
worsening in not more than one variable by more than 30%.
Current therapeutic options
Treatment of patients with systemic JIA remains a challenge. 
Many different treatment regimens with immunosuppressants 
have been used. Although corticosteroids have been the main-
stay of therapy for children with active systemic JIA, there is no 
evidence that systemic corticosteroids are disease modifying. 
Due to unacceptable, deleterious long-term side effects such 
as growth retardation, osteoporosis, and diabetes, reduction 
of corticosteroid dosage and prevention of prolonged therapy 
is mandatory. Instead of high-dose daily oral corticosteroids 
pulses with high-dose intravenous methylprednisolon (up to 
30 mg/kg per dose, maximal 1000 mg have been proposed 
to minimize side effects.20 In a few patients, nonsteroidal 
anti-inflammatory drugs (NSAIDs) alone have been effective. 
More often methotrexate either given orally or subcutane-
ously have been used as a second-line medication in systemic 
JIA but has been less effective compared to the use in treating 
polyarticular JIA.21 Biological therapy with anti-TNFα agents 
have limited effect in systemic JIA with response rates as low 
as 30%.22,23 Pascual and colleagues24 demonstrated that sera 
from nine patients with systemic JIA provoked IL-1 synthesis 
Table 1 Core set of criteria for evaluating change in treatment 
trials of children with juvenile idiopathic arthritis:   American College 
of rheumatology Pediatric response criteria19
1.    Number of active joints (swollen joints and/or two or three of the 
following: limitation of range of motion, pain on motion, and increased 
heat of joints).
2.    Number of joints with limited range of motion.
3.    Physician global assessment of disease activity.
4.    Patient/parent assessment of overall well being.
5.    Functional ability (Childhood Health Assessment Questionnaire).
6.    Erythrocyte sedimentation rate.
Notes: improvement is at least 30% improvement from baseline in three of any six 
variables with no more than one of the remaining variables worsening by 30%.Core Evidence 2009:4 184
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in tissue culture of mononuclear cells. In seven of these nine 
patients, treatment with anakinra, an anti-IL-1 receptor 
antagonist, gave a complete clinical response. In an open-label 
study, 20 patients with systemic JIA refractory to corticosteroids 
were treated with anakinra 1–2 mg/kg/day. Only moderate 
response rates were found with an ACRPed30, 50, and 70 of 
55%, 30%, and 0%, respectively, after three months and after 
six months 50%, 25% and 10%, respectively.25 A multicenter, 
randomized double-blind trial of anakinra versus placebo in 
systemic JIA with 12 patients in each group has been con-
ducted and preliminary results were presented.26 Achievement 
of ACRPed30 response along with resolution of fever and 
normalization of CRP after one month was seen in 8/12 in 
the anakinra group compared to 1/12 in the placebo group. 
Because daily subcutaneous injections are required and 
are painful, the practical use of anakinra has been limited. 
A long-acting soluble receptor-based IL-1 blocker, rilonacept 
(IL-1 Trap), has been investigated in a phase II trial in 
systemic JIA. Preliminary results published in abstract form 
from the open-label phase including 21 patients have revealed 
improvement after four weeks with ACRPed30, 50, and 
70 responses of 76.2%, 61.9%, and 33%, respectively.27 Fever 
and/or rash was completely resolved. Sustained response 
was recorded in 12 patients. Treatment with rilonacept was 
generally safe and well tolerated.
Tocilizumab
The blockade of the biological functions of IL-6 may theoreti-
cally be available through a blockade of the gp130 receptor 
by neutralizing IL-6 or by the prevention of the IL-6/IL-6R 
complex formation. Since the gp130 homodimer is shared 
among other receptors than for IL-6, the blockade of gp130 
may implicate a wide range of undesirable effects. Attempts 
of trials with chimaeric anti-IL-6 monoclonal antibody have 
failed to block IL-6 function.28,29
Tocilizumab, formerly myeloma receptor antibody 
(MRA), is a humanized anti-IL-6R monoclonal antibody 
(humanized by the technique of complementary-determining 
region grafting from mouse anti-human IL-6R monoclonal 
antibody) engrafted with a human IgG1 Fc to minimize 
potential immunogenic responses in humans.30 It has a high 
affinity to IL-6R and abrogates the IL-6 signaling by prevent-
ing the formation of the IL-6/IL-6R complex.
The clinical efficacy of tocilizumab in preliminary stud-
ies has previously been described in murine experimental 
arthritis,31 in patients with RA,32–34 multicentric plasma cell 
type or mixed type Castleman’s disease35 and adult-onset 
Still’s disease.36
Clinical efficacy of tocilizumab  
in adults with rA
Tocilizumab was launched in April 2008 in Japan and 
was approved by the European Agency for the Evaluation 
of Medicinal Products (EMEA) in January 2009 for the 
treatment of moderate and severe RA, but has not yet been 
approved by the US Food and Drug Administration (FDA). 
Results from randomized controlled trials of tocilizumab in 
RA are summarized in Table 1. In the CHARISMA study,37 
a phase II study evaluating the efficacy of tocilizumab in 
359 patients with active RA and with an inadequate response 
to methotrexate, patients were randomized to seven study 
arms evaluating the effect of three doses of tocilizumab: 2, 4, 
and 8 mg/kg with or without methotrexate plus methotrexate 
alone. The infusion of tocilizumab was given at four-week 
intervals. ACR20 responses were achieved in all tocilizumab 
arms at doses of 4 and 8 mg/kg (Table 2).
Four phase III randomized, double-blind placebo-
controlled trials evaluating the effect of tocilizumab versus 
placebo in a total of 2,467 patients with RA have been pub-
lished since 2008.38–41 In all studies with RA, tocilizumab was 
infused at four-week intervals. The most significant results 
were observed with doses of 8 mg/kg with achievement 
of ACR20 responses of 50%–80.3%, ACR50 responses 
of 29%–49%, and ACR70 responses of 12.4%–29.5%. 
Remission, defined as Disease Activity Score (DAS28) 2.6, 
were observed in 27%–43.1% of patients receiving 8 mg/kg 
doses compared with 7.6%–13% of patients receiving 4 mg/kg 
in the OPTION and RADIATE trials.
In the SAMURAI study, a randomized X-ray double-
blind controlled trial, Nishimoto and colleagues42 evaluated 
the ability of tocilizumab monotherapy against conventional 
DMARDs to inhibit progression of structural joint dam-
age in RA patients. After 52 weeks, the tocilizumab group 
showed significantly less radiographic change in the van 
der Heijde score (modified Sharp score) (mean 2.3, 95% 
confidence interval [CI]: 1.5–3.2; p  0.01) compared to 
the DMARD group (mean 6.1, 95% CI: 4.2–8.0; p  0.01). 
Erosion score was 0.9 and joint space narrowing was 1.5 in 
the tocilizumab group versus 3.2 and 2.9 in the DMARD 
group, respectively.
Clinical efficacy of tocilizumab  
in systemic onset JIA
Two phase II studies of the blockade of IL-6 signaling using 
anti-IL-6 receptor antibody (MRA, tocilizumab) for systemic 
JIA suggested that it was a highly effective treatment.43,44 Core Evidence 2009:4 185
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Yokota and colleagues43 evaluated the safety and efficacy of 
tocilizumab in a dose-escalating protocol (MRA011JP) in 
11 Japanese children (3–18 years) with active systemic onset 
JIA refractory to corticosteroids and/or DMARDs. Primarily 
Yokota and colleagues infused a 2 mg/kg/dose three times with 
a two-week interval. The dose was increased to 4 mg/kg and 
administered three times if CRP level were above 1.5 mg/dl 
after the first and second infusion and further to 8 mg/kg 
three times if CRP was still above 1.5 mg/dL. Tocilizumab 
abruptly reduced disease activity in 10 of the 11 children two 
weeks after the administration of the drug. Three children had 
sustained response to 2 mg/kg, five of the remaining eight 
children were stabilized with 4 mg/kg, and three children 
received 8 mg/kg before CRP was kept below 1.5 mg/dL. In 
total, ACRPed30 and ACRPed50 was achieved in 10 children 
and ACRPed70 was achieved in seven children.
In another open-labelled trial (LRO320), 15 of 18 enrolled 
Caucasian children with systemic JIA received a single dose 
of either 2 mg/kg (n = 4), 4 mg/kg (n = 6), or 8 mg/kg (n = 5) 
tocilizumab by infusion.44 All had active disease for at least 
three months with at least one active systemic feature, one 
active joint, and prednisolone doses above 0.2 mg/kg/day and 
in addition 12 also received methotrexate (20 mg/m2/week). 
Although only a small number of patients were studied, there 
was a marked improvement in all patients within all three 
dose groups 48 hours after the infusion and at one-week 
follow-up, 11 patients achieved ACRPed30, eight patients 
achieved ACRPed50, and three achieved ACRPed70. 
However, a prolonged clinical response was only observed 
for 4 mg/kg and 8 mg/kg with an ACRPed30 obtained in 
6/9 patients. Along with the clinical improvement, a marked 
decrease in CRP and ESR after one week was followed by 
an increase shortly after.
While writing this review, only one randomized double-
blind, placebo-controlled withdrawal study (MRA316JP) of 
the effect of tocilizumab for the treatment of Japanese children 
with systemic JIA has been published.45 The study included an 
open-label lead-in phase of six weeks, a double-blind, random-
ized, placebo-controlled withdrawal phase of 12 weeks, and 
an open-label extension phase of 48 weeks or more. Fifty-six 
children (21 boys, 35 girls) with active systemic JIA defined 
by an increase in CRP  15 mg/L and inadequate clinical 
response to 0.2 mg/kg/day of prednisolone were enrolled 
in the open-label lead-in phase. They received 8 mg/kg tocili-
zumab three times every two weeks with a primary endpoint 
being ACRPed30 (Table 3). After six weeks, ACRPed30, 50, 
and 70 was achieved in 91%, 86%, and 68%, respectively. 
Forty-three patients continued to the double-blind withdrawal 
phase and were randomly assigned to either receive an infu-
sion of tocilizumab 8 mg/kg or placebo every two weeks 
for 12 weeks. In the tocilizumab group 80% maintained an 
ACRPed30 or ACRPed50 response and a CRP concentration 
15 mg/l after 12 weeks compared to 17% in the placebo 
group (p  0.0001) (Table 4). Half of the children in the pla-
cebo group who did not maintain ACRPed30 relapsed within 
four weeks. In the open-labeled extension phase, 48 of the 
Table 2 randomized controlled trials of tocilizumab in rheumatoid arthritis
Trial name Author Design No of 
patients
Duration Study arms  
tocilizumab in 
mg/kg/4 weeks
ACR20 ACR50 ACR70 DAS28  2.6
CHAriSMA Maini et al37 r-DB-PC 359 16 wk 0 + mtx 
2/2 + mtx 
4/4 + mtx 
8/8 + mtx
41 
31/64 
61/63 
63/74
29 
6/32 
28/37 
41/53
8 
2/14 
6/12 
16/37
– 
– 
– 
–
OPTiON Smolen et al38 r-DB-PC 623 24 wk 0 + mtx 
4 + mtx 
8 + mtx
26 
48 
59
11 
31 
44
2 
12 
22
0.8 
13 
27
TOwArD Genovese et al39 r-DB-PC 1220 24 wk 0 + DMArD 
8 + DMArD
25 
61
9 
38
3 
21
3 
30
rADiATE Emery et al40 r-DB-PC 499 0 + mtx 
4 + mtx 
8 + mtx
10 
30 
50
4 
17 
29
1.3 
5 
12.4
1.6 
7.6 
30.1
SATOri Nishimoto et al41 r-DB-PC 125 24 wk placebo + mtx 
toc 8 + placebo
25 
80.3
10.9 
49.2
6.3 
29.5
1.6 
43.1
Abbreviations: ACr,   American College of rheumatology; DAS, Disease Activity Score; DMArD, disease-modifying antirheumatic drug; mtx, methotrexate; r-DB-PC, 
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50 patients continued to receive tocilizumab after 48 weeks. 
Achievement of ACRPed 30, 50, and 70 was observed in 98%, 
94%, and 90%, respectively. The median percentage change 
in ESR and CRP was -93.2% and -99.7%, respectively, along 
with a significant increase in hemoglobin.
In 2008, an ongoing two-part phase III multicenter study 
(WA18221) consisting of a part I 12-week randomized, 
double-blind, placebo-controlled two-arm study evaluating the 
efficacy and safety of tocilizumab in patients with systemic 
JIA was launched with a subsequent part II 92-week single-
arm open-label extension study to examine the long-term use 
of tocilizumab. Pediatric rheumatology centers from Europe, 
North America, and South America are participating in the 
study. The patients are randomized to either 8 mg/kg for patients 
30 kg every two weeks and 12 mg/kg for patients 30 kg 
or placebo infusions every two weeks. The patients (n = 108) 
are unequally randomized (tocilizumab/placebo ratio 2:1). 
The primary efficacy endpoints are the proportion of patients 
with at least 30% improvement in JIA core set (ACRPed30) 
at week 12 and absence of fever. The rationale for using the 
increased dose (12 mg/kg) for small children 30 kg was 
chosen as a consequence of the pharmacokinetic, safety, and 
efficacy data from the MRA316JP study.
Clinical efficacy in oligo-  
and polyarticular onset JiA
In a case report, a 26-year-old woman with oligoarthritis for 
12 years was described having developed amyloidosis in 
the kidney and intestines. The patient responded well to the 
treatment of intravenous 8 mg/kg tocilizumab given every 
3–4 weeks.46
One prospective, open-labeled, multicenter study 
has been performed in patients with polyarticular or 
oligoarticular onset JIA with a polyarticular course.47 
The children were treated with 8 mg/kg tocilizumab every 
four weeks for 48 weeks. Concomitant treatments with 
other biologics, DMARDs, or immunosuppressants were 
not allowed. Nineteen patients were enrolled in the study 
with the primary efficacy endpoint being the proportion of 
patients achieving ACRPed30, 50, and 70 every 12 weeks 
from the baseline evaluation. They found a significant 
decrease in all core set parameters with an ACRPed30 
of 94.1% after 12 weeks. The response continued until 
the evaluation after 48 weeks where 11 completed the 
assessments (ACRPed30, 100%; ACRPed50, 100%; 
ACRPed70, 90.9%).
Safety and tolerability
In the phase II study, Yokota and colleagues,43 reported 
that the drug was generally well tolerated at all doses. 
Two patients had upper respiratory tract infections and three 
had pustules on the extremities. In four patients, cholesterol 
increases were observed, two patients showed elevated 
alanine aminotransferases, and two showed glucosuria. 
Woo and colleagues44 reported no evidence of dose-limiting 
toxicity. Fifty-nine adverse events were reported in 15 patients 
with mainly gastroenteritis and respiratory disorders. Three 
had elevated alanine aminotransferases and one had urticaria. 
No serious bacterial infections were seen.
Two serious adverse events were reported in in the 
lead-in phase of the phase III study (MRA316JP):45 one 
with anaphylaxis and one with gastrointestinal hemorrhage 
from colonic ulceration in a patient with previous history of 
diarrhea and rectal bleeding. In the double-blind phase, one 
patient had infectious mononucleosis with highly elevated 
liver transaminases and neutropenia and one developed 
herpes zoster.
To evaluate the long-term safety of tocilizumab, 128 patients 
with systemic JIA including patients who completed the 
MRA011JP and MRA316JP studies and an additional 
61 patients were enrolled.48 Tocilizumab was administered as 
an infusion of 8 mg/kg every two weeks. The median dura-
tion of tocilizumab treatment was 78 weeks. Adverse events 
occurred in 120 patients (94%) at a rate of 787 per 100 patient-
years. Serious adverse events occurred at an incidence rate 
of 37.2 per 100 patient years and serious infections at a 
rate of 14.5 per patients-years. The most frequent serious 
Table 3 response to tocilizumab 8 mg/kg every two weeks in 
patients with systemic onset juvenile idiopathic arthritis in a six 
week open-label lead-in phase45
  Number of pts. (%)
ACrPed30 51/56 (91%)
ACrPed50 48/56 (86%)
ACrPed70 38/56 (68%)
Abbreviation: ACrPed,   American College of rheumatology Pediatric criteria.
Table 4 Maintained ACrPed response after a 12-week double-blind 
phase continuing with either tocilizumab 8 mg/kg every two weeks 
or placebo45
  Tocilizumab Placebo p value
ACrPed30 16/20 (80%) 4/23 (17%) p  0.0001
ACrPed50 16/20 (80%) 4/23 (17%) p  0.0001
ACrPed70 15/20 (75%) 3/23 (13%) p  0.0001
Abbreviation:   ACrPed,   American College of rheumatology Pediatric criteria.Core Evidence 2009:4 187
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infections were gastroenteritis (3.8/100 patient-years) and 
pneumonia (3.4/100 patient-years). In total, 14 patients were 
withdrawn from the study. Eight patients were withdrawn 
from the study due to adverse events which included 
macrophage activation syndrome, anaphylactoid reaction (two 
patients), cardiac amyloidosis, duodenal perforation, gastro-
intestinal hemorrhage, and infusion reactions (two patients). 
Furthermore, five patients were withdrawn from the study due 
to the development of antitocilizumab antibodies and one due 
to lack of efficacy.
Place in therapy for tocilizumab in JiA
With the advent of biological response modifiers, commonly 
referred to as biologics, the therapeutical options for JIA have 
improved considerably. The use of TNFα inhibitors for the 
treatment of JIA with a polyarticular course refractory to 
conventional methotrexate has shown efficacy in controlled 
clinical trials with etanercept, infliximab, and adalimumab.49 
A long-term follow-up study with etanercept has shown 
a sustained effect and with relatively few serious adverse 
events and high tolerability.50
However, children with systemic onset JIA may often 
be refractory to treatment with both conventional DMARDs 
and biologics. Response rates as low as 30% using etanercept 
have been shown23 and often unacceptably high doses of 
corticosteroids are used to control the disease. Only one phase 
III double-blind placebo-controlled withdrawal study with 
tocilizumab has been published so far in systemic JIA.45
The study design, combining an open-label lead-in 
phase with a placebo-controlled withdrawal phase, has 
been used for studying biologics in JIA randomized 
controlled trials for the last decade and is considered 
ethically acceptable for the use in children. Tocilizumab 
infusions of 8 mg/kg every other week achieved high 
response rates with an ACRPed50 of 86%. Compared to 
this, tocilizumab 8 mg/kg given every four weeks to adult 
patients with RA resulted in an ACR50 of 29%–49% in 
four phase III studies.
Response to tocilizumab therapy is seen with few weeks 
and even days. The drug is generally well tolerated with an 
incidence of serious adverse events of 37/100 patient-year. 
The most frequent serious infections are gastroenteritis and 
pneumonia, at 3.8 and 3.4/100 patient-years, respectively.
If the ongoing double-blind placebo-controlled 
tocilizumab randomized controlled trial (WA18221) 
for systemic JIA shows comparable results as in the 
Japanese study, tocilizumab could be considered as a 
first-line drug in corticosteroid-resistant systemic JIA. 
However, direct comparison of treatment with tocilizumab 
and TNFα-inhibitors or other biologics like abatacept or 
IL-1R inhibitors in head-to-head or crossover studies could 
be warranted to elucidate its role in the therapeutic option 
of systemic JIA.
There is still very limited information regarding the 
pharmacoeconomic aspects of the treatment of children with 
JIA with tocilizumab.
In summary, tocilizumab is an effective drug for the 
treatment of systemic onset JIA. It represents an interesting 
option for patients refractory to or dependent on corticoste-
roid therapy. Full data are not yet available to place its role 
in the treatment of nonsystemic JIA where other biologics 
have shown a higher efficacy. However, the significant effect 
on adult RA may indicate that tocilizumab could also have 
a promising role for polyarticular JIA.
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